In spite of evidence from studies such as AcroVoice [3] that highlight the beneficial effect of patient-centred parameters on disease activity, Marazuela et al. recently showed that IGF-I and tumour mass control are still the main drivers of treatment change, and that patient-centred parameters such as QoL or symptoms were not always considered [30]. This evidence concerns the gene IGF1 and neoplasm.